Monograph
B01AC06 - Acetylsalicylic Acid |
Propably not porphyrinogenic |
PNP |
Rationale
Inducer of 2C19. By vast experience known not to be porphyrinogenic. Several references: safe/authorised.
Chemical description
Water soluble platelet inhibitor, administered as tablets 75-500 mg/d. Hydrolyzed to salicylic acid. Excreted in urine. French list: Authorized. Kalman, Bonkowski: Believed to be safe. Moore MR, Hift RJ: Drugs in acute porphyria. Cell Mol Biol 43:89,1997: safe. Eales L: Porphyria and the lifethreatening drugs. S Afr Med J 56:914, 1974: safe. C.Andersson; patient reports: tolerated (n=2)
IPNet drug reports
Uneventful use reported in 92 patients with acute porphyria.
Similar drugs
Tradenames and packages
From some sources, we get a list of packages (United Kingdom, Ireland, Estonia).
Other sources contain more or less "clean" versions of the trade name (Denmark, Finland, Iceland, Lithuania, Norway).
What you see here is the raw data we get from each country, so there will appear to be duplicates. The bold names
are the searchable terms. The gray names that follow are all mapped to the bolded term.
Note: The cleaning is done automatically by a proprietary algorithm, and it may produce errors.
We strive to improve it continuously.
Netherlands
Belgium
United Kingdom
Denmark
Norway
Poland
Luxembourg
Iceland
Finland
Latvia
Serbia
